about
Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritisCombination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single componentsCXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritisThe cation channel Trpv2 is a new suppressor of arthritis severity, joint damage, and synovial fibroblast invasionThe arthritis severity locus Cia5a regulates the expression of inflammatory mediators including Syk pathway genes and proteases in pristane-induced arthritis.Increased synovial expression of nuclear receptors correlates with protection in pristane-induced arthritis: a possible novel genetically regulated homeostatic mechanism.Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onsetTreatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis.The ICIDH-2 as a framework for the assessment of functioning and disability in rheumatoid arthritisAnticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage.MRI of the wrist in early rheumatoid arthritis can be used to predict functional outcome at 6 years.T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritisPrognostic laboratory markers of joint damage in rheumatoid arthritis.Identification of two new arthritis severity loci that regulate levels of autoantibodies, interleukin-1β, and joint damage in pristane- and collagen-induced arthritisAutoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis.
P2860
Q24684208-BDD19680-CEBC-44FF-88E0-0345978462B9Q28343376-4CC23061-616E-472E-87DB-81D9782FC91FQ28569526-EA52C38C-81A8-4072-952E-15E8122D4C63Q28573570-308D2E51-6C40-4A69-9BBD-D8E5B3C9EDB2Q34515149-ED0C0818-474E-4789-9BE9-E9D7D4E9964DQ35243488-7E0F4C1C-0986-4383-BF90-4F08A512F2FBQ35547914-BFD57607-546D-40F4-AB15-EF7B228B0BAFQ35550470-5D6908DB-11D5-42DB-BC45-21DB74D95288Q35551415-9347A1B1-84D1-4097-A166-AD49CF8700D6Q35552357-27AD5623-3DA5-4EC1-A579-420809F349F7Q35554101-22F4647A-2928-41E4-9C23-4605FC6E6E5FQ35554105-9F0D14A9-54D7-4A51-A4AF-D8CA4B7FEA54Q35555179-2F8316FB-479C-41B8-859F-8E8A37182DE7Q35784822-D51E53E7-0EBA-48BB-A41C-5B2D891E9543Q41824468-F8CA09C7-57F2-4717-A750-52D566FE2802
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Prognostic factors in rheumatoid arthritis.
@en
type
label
Prognostic factors in rheumatoid arthritis.
@en
prefLabel
Prognostic factors in rheumatoid arthritis.
@en
P1476
Prognostic factors in rheumatoid arthritis.
@en
P2093
Breedveld FC
van Zeben D
P577
1996-03-01T00:00:00Z